Long-Term Use of Topical Treatments in Atopic Dermatitis

Delgocitinib Data Reveal "Super Responders" in CHE During AAD 2025 Late Breaker

AAD 2025. Guttman, among the world's foremost researchers in dermatology, toplined how far the field has come in her "Hot Topics" presentation on the final day of the 2025 AAD.

Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings

Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.

Atopic Dermatitis Breakthrough: Linda Stein Gold, MD, on Tapinarof's Treatment-Free Benefits

Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.

Dupilumab Demonstrates Superior Long-Term Persistence Over Upadacitinib and Tralokinumab in Atopic Dermatitis

AAD 2025. Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial.

Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation

Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.

March 8th 2025

For Atopic Dermatitis, "The Treatment Drought is Over," Says Expert Dermatologist Emma Guttman, MD, PhD

AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.

Related Content

Delgocitinib Data Reveal "Super Responders" in CHE During AAD 2025 Late Breaker

AAD 2025. Guttman, among the world's foremost researchers in dermatology, toplined how far the field has come in her "Hot Topics" presentation on the final day of the 2025 AAD.

Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings

Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.

Atopic Dermatitis Breakthrough: Linda Stein Gold, MD, on Tapinarof's Treatment-Free Benefits

Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.

Dupilumab Demonstrates Superior Long-Term Persistence Over Upadacitinib and Tralokinumab in Atopic Dermatitis

AAD 2025. Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial.

Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation

Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.

March 8th 2025